Exosomes Early Promise

Exosomes Early Promise

Exosome therapy is a burgeoning field in regenerative medicine and is now being offered in many US clinics. This therapy has the potential to regenerate, heal, and repair but many claims being made are not yet supported by scientific studies. Although the scientific...
Expanded Access

Expanded Access

Expanded access or compassionate use is an FDA program that under certain conditions allows the use of an investigational new drug (IND) or biologic to treat a patient with a serious or life-threatening disease or condition who does not meet the enrollment criteria...
Eligibility for Right to Try

Eligibility for Right to Try

The Right to Try Act was passed into federal law in 2018. It provides a new channel for eligible patients to request access to investigational drugs outside of any FDA clinical trials. Often, clinical trials are not available, too restrictive, or too far a distance...
Stem Cell Therapy: The Right to Try Act

Stem Cell Therapy: The Right to Try Act

The federal Right to Try Act was passed in May of 2018. The Act provides federally-protected rights for access to potentially life-saving investigational drugs prior to FDA final approval.  These protected rights are for patients in the United States who suffer from...
Stem Cells and Anti-Aging

Stem Cells and Anti-Aging

Stem cells are medicinal and a promising solution for slowing and potentially reversing certain elements of aging. These cells have the ability to home to sites of injury or disease and secrete growth factors and other intercellular signaling that can either stimulate...
Who Named Mesenchymal Stem Cells?

Who Named Mesenchymal Stem Cells?

Mesenchymal stem cells (MSCs) were named by Dr. Arnold Caplan in his publication titled Mesenchymal Stem Cells, Journal of Orthopedic Research in 19911. MSCs are adult stem cells that can be isolated from different sources including bone marrow, fat/adipose tissue,...